Barr Gets FDA Green Light For Allegra-D Amid Patent Dispute

Law360, New York (April 15, 2005, 12:00 AM EDT) -- The U.S. Food and Drug Administration has granted Barr Laboratories a final approval for a generic version of Aventis Pharmaceuticals' blockbuster allergy medicine Allegra-D, the company said.

The move would give Barr the right to make a generic version of the 12-hour 60mg and 120 mg extended-release tablets if the company prevails in a patent challenge against the French drug maker.

Barr is the first applicant to file an abbreviated New Drug Application containing a paragraph IV patent challenge on the patents relating to the Allegra-D...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.